Option Care Health, Inc.
NASDAQ•OPCH
CEO: Mr. John C. Rademacher
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 1996-08-15
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
連絡先情報
3000 Lakeside Drive, Suite 300N, Bannockburn, IL, 60015, United States
312-940-2443
時価総額
$5.72B
PER (TTM)
27.5
33.5
配当利回り
--
52週高値
$36.80
52週安値
$24.24
52週レンジ
順位44Top 53.8%
3.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$1.44B+12.24%
直近4四半期の推移
EPS
$0.32+0.00%
直近4四半期の推移
フリーCF
$157.90M+4.76%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Net Revenue Increased 12.2% Net Revenue for Q3 2025 reached $1.44B USD, marking a 12.2% increase over Q3 2024 results driven by organic growth.
Gross Profit Rises Moderately Q3 Gross Profit increased by $16.2M USD to $272.9M USD, reflecting growth in revenue and therapy mix compared to prior year.
Intramed Plus Acquisition Closed Acquired Intramed Plus for $117.2M USD net cash, adding $66.4M USD in goodwill during the nine months period.
Strong Stock Repurchase Activity Company spent $212.5M USD on share repurchases in nine months; $287.5M USD remains authorized for future buybacks.
リスク要因
Gross Margin Compression Noted Q3 Gross Margin fell to 19.0% from 20.1% due to certain higher cost therapies included within chronic growth segments.
Operating Cash Flow Decreased Nine Months Cash from Operations dropped $64.7M USD to $222.6M USD, impacted by working capital usage and inventory increases.
Debt Refinancing Impact Recognized Debt refinancing incurred a $4.7M USD loss on extinguishment and $6.7M USD in issuance costs during the quarter.
Supplier Concentration Exists 66% to 67% of pharmaceutical and supply purchases rely on just four vendors, posing potential service delivery delays risk.
見通し
Liquidity Position Remains Stable Existing cash balances and expected operating cash flows are believed sufficient to meet operating requirements over the next 12 months.
Debt Structure Optimized Post-Refinance Fourth Amendment reduced First Lien Term Loan rate and extended maturity to September 22, 2032, enhancing terms.
Acquisitions Remain Key Strategy Company continues to evaluate acquisition opportunities as a key part of growth strategy, potentially requiring additional capital.
Interest Rate Hedge Active Interest rate cap hedge remains active for five years, partially offsetting risk associated with the First Lien Term Loan variable rate.
同業比較
売上高 (TTM)
OSCR$11.70B
$5.53B
$2.53B
粗利益率 (最新四半期)
NAMS100.0%
CRNX100.0%
ACAD92.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CHE | $6.89B | 24.7 | 24.4% | 8.7% |
| KYMR | $6.70B | -25.1 | -33.4% | 7.6% |
| OPCH | $5.72B | 27.5 | 15.3% | 36.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.1%
緩やかな成長
4四半期純利益CAGR
-4.8%
収益性の安定
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年2月24日
EPS:$0.46
|売上高:$1.46B
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年10月30日|売上高: $1.44B+12.2%|EPS: $0.32+0.0%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年7月30日|売上高: $1.42B+15.4%|EPS: $0.31+0.0%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年4月29日|売上高: $1.33B+16.3%|EPS: $0.28+7.7%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月26日|売上高: $5.00B+16.2%|EPS: $1.23-17.4%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年10月30日|売上高: $1.28B+17.0%|EPS: $0.32+3.2%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年7月31日|売上高: $1.23B+14.8%|EPS: $0.31-51.6%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年4月23日|売上高: $1.15B+12.8%|EPS: $0.26+18.2%予想を上回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月22日|売上高: $4.30B+9.1%|EPS: $1.49+79.5%予想を上回る